Kieran O'Kane - Feb 23, 2021 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Commercial Officer
Signature
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
Feb 23, 2021
Transactions value $
$0
Form type
4
Date filed
7/26/2023, 06:14 PM
Next filing
Feb 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Stock Options (Right to buy) Award $0 +25.6K $0.00 25.6K Feb 23, 2021 Common Stock 25.6K $20.67 Direct F1
transaction BDSX Stock Options (Right to buy) Award $0 +31.1K $0.00 31.1K Feb 23, 2021 Common Stock 31.1K $20.67 Direct F2
transaction BDSX Stock Options (Right to buy) Disposed to Issuer -25.6K -100% 0 Jul 24, 2023 Common Stock 25.6K $20.67 Direct F1, F3, F4
transaction BDSX Stock Options (Right to buy) Disposed to Issuer -31.1K -100% 0 Jul 24, 2023 Common Stock 31.1K $20.67 Direct F2, F3, F4
transaction BDSX Stock Options (Right to buy) Award +11.6K 11.6K Jul 24, 2023 Common Stock 11.6K $1.20 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.
F2 This option was fully vested as of the grant date.
F3 On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.
F4 The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.
F5 This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.